MDxHealth establishes US CLIA laboratory in Irvine, CA, and makes key hires to expand US team
18. August 2011 02:00 ET
|
mdxhealth
DURHAM, NC, and LIEGE, BELGIUM - August 18, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, announced today that it has signed...
Le biomarqueur de MDxHealth participe à une importante étude clinique sur le cancer du côlon initiée par Exact Sciences
03. August 2011 02:00 ET
|
mdxhealth
DURHAM, NC, et LIEGE, BELGIQUE - le 3 août, 2011 - MDxHealth SA (NYSE Euronext: MDXH), un leader du diagnostic moléculaire dans le domaine de la médecine personnalisée a annoncé aujourd'hui que son...
MDxHealth's biomarker part of large pivotal colon cancer trial initiated by Exact Sciences
03. August 2011 02:00 ET
|
mdxhealth
DURHAM, NC, and LIEGE, BELGIUM - August 3, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, announced today that its licensing...
MDxHealth's MGMT Test Shown to Be Only Prognostic Factor in Journal of Clinical Oncology Report on Newly Diagnosed Brain Cancer Patients
11. Juli 2011 02:00 ET
|
mdxhealth
DURHAM, NC, and LIEGE, BELGIUM - July 11, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that its...
Assemblée Générale Extraordinaire des Actionnaires
23. Juni 2011 02:00 ET
|
mdxhealth
DURHAM, NC, et LIEGE, BELGIQUE - le 23 juin, 2011 - MDxHealth SA (NYSE Euronext: MDXH), un leader du diagnostic moléculaire dans le domaine du traitement personnalisé du cancer, a tenu le 21 juin 2011...
Extraordinary General Shareholders' Meeting
23. Juni 2011 02:00 ET
|
mdxhealth
DURHAM, NC, and LIEGE, BELGIUM - June 23, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, held an extraordinary...
MDxHealth et Merck KGaA étendent leur contrat de collaboration relatif à l'utilisation du test MGMT dans les études cliniques portant sur le cancer du cerveau
09. Juni 2011 02:30 ET
|
mdxhealth
DURHAM, NC et LIEGE, BELGIQUE - le 9 juin 2011 - MDxHealth SA (NYSE Euronext: MDXH), un leader du diagnostic moléculaire dans le domaine de la médecine personnalisée, a annoncé aujourd'hui étendre son...
MDxHealth and Merck KGaA extend Agreement for use of MGMT Assay in Brain Cancer Clinical Trials
09. Juni 2011 02:30 ET
|
mdxhealth
DURHAM, NC, and LIEGE, BELGIUM - June 9th, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, announced today that it will extend...
Le test MGMT de MDxHealth identifie les patients atteints d'un cancer du cerveau susceptibles de vivre plus longtemps avec un traitement au Témozolomide
06. Juni 2011 02:00 ET
|
mdxhealth
Rudi Mariën rejoint le Conseil d'Administration DURHAM, NC, et LIEGE, BELGIQUE - le 6 juin 2011 - MDxHealth SA (NYSE Euronext: MDXH), un leader du diagnostic moléculaire dans le domaine du...
MDxHealth's MGMT Test Identifies Brain Cancer Patients Likely to Live Longer on Temozolomide Treatment - Phase III Data Presented at ASCO
06. Juni 2011 02:00 ET
|
mdxhealth
DURHAM, NC, and LIEGE, BELGIUM - June 6, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that its MGMT...